Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €48.16 EUR
Change Today +0.043 / 0.09%
Volume 0.0
IM5 On Other Exchanges
Symbol
Exchange
Berlin
As of 3:00 PM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

alere inc (IM5) Snapshot

Open
€48.23
Previous Close
€48.11
Day High
€48.31
Day Low
€48.08
52 Week High
07/3/15 - €48.31
52 Week Low
08/13/14 - €25.37
Market Cap
4.1B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
85.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALERE INC (IM5)

alere inc (IM5) Related Businessweek News

View More BusinessWeek News

alere inc (IM5) Details

Alere Inc. provides point-of-care diagnostics and services for infectious disease, cardiometabolic disease, and toxicology in the United States and internationally. The company operates through Professional Diagnostics and Consumer Diagnostics segments. Its cardiometabolic products and services include tests to assist in the diagnosis and management of various cardiometabolic factors and conditions, including cardiac markers, glucose and HbA1C, cholesterol levels, blood gases, and home monitoring for VAD and oral anticoagulation. These meters and tests are used in hospital urgent care, laboratory, doctor’s office, or at home. The company’s infectious disease products and services comprise tests to assist in the diagnosis and management of infectious diseases, such as HIV, malaria, syphilis, E. coli, and influenza. The infectious disease diagnostic tests and monitoring devices provide results for approximately 75 types of infectious diseases, including those caused by bacteria, viruses, fungi, or parasites. Its drug and alcohol testing portfolio includes rapid analyzer-based tests, visual-read screening devices, laboratory tests, and immunoassay reagents. The company’s toxicology products are used in hospitals, clinics, physician offices, criminal justice systems, workplace, rehabilitation, occupational health clinics, home testing, and other. Alere Inc. also delivers services and solutions across various environments, including clinical immunology, women's health, and oncology. It markets its professional diagnostic products through its sales force and distribution networks; and First Check consumer drug testing products through retail drug stores, drug wholesalers, groceries, and mass merchandisers. The company was formerly known as Inverness Medical Innovations, Inc. and changed its name to Alere Inc. in July 2010. Alere Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

9,800 Employees
Last Reported Date: 05/28/15
Founded in 1981

alere inc (IM5) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $882.1K
Global President of Toxicology
Total Annual Compensation: $650.0K
Global President of Cardiometabolic Business ...
Total Annual Compensation: $548.1K
Global President of Infectious Disease Busine...
Total Annual Compensation: $486.3K
Executive officer
Total Annual Compensation: $425.1K
Compensation as of Fiscal Year 2014.

alere inc (IM5) Key Developments

Alere Inc. Announces Completion of Offering of $425 Million of Senior Subordinated Notes

Alere Inc. announced that it has completed its previously announced offering of $425 million of senior subordinated notes. The notes will bear interest at a rate of 6.375% per year, payable semi-annually on January 1 and July 1 of each year, beginning on January 1, 2016, and will mature on July 1, 2023 unless earlier redeemed. The company intends to use the net proceeds from the offering to redeem, effective as of October 1, 2015, all of its outstanding $400 million aggregate principal amount of 8.625% senior subordinated notes due 2018 and to pay a portion of related redemption fees, premiums, costs and expenses and accrued interest on such notes. The company exercised its right immediately to satisfy and discharge all of its obligations with respect to the 8.625% senior subordinated notes, subject to settlement of the redemption on October 1, 2015. As a result of this refinancing, the company expects to save approximately $2 million in quarterly interest expense.

Alere Inc. Announces Refinancing of Senior Secured Credit Facilities

Alere Inc. announced that it has closed new senior secured credit facilities totaling $1.95 billion and used a portion of the proceeds thereof to repay in full and terminate its existing secured credit facilities. Goldman Sachs Bank USA, GE Capital Markets Inc., J.P. Morgan Securities LLC, DNB Markets Inc., RBC Capital Markets, HSBC Securities (USA) Inc. and Citizens Bank, N.A. acted as joint lead arrangers for the new credit facilities. Goldman Sachs Bank USA will serve as the B term loan administrative agent and General Electric Capital Corporation will serve as the collateral agent and pro rata administrative agent for the lenders under the credit facilities. The new credit facilities consist of term loan facilities totaling $1.7 billion and a $250 million revolving credit facility. The term loans, all of which were drawn at closing, consist of $650 million of A term loans and $1.05 billion of B term loans. No amount was drawn under the revolving credit facility at closing. The A term loans and the company's borrowings pursuant to the revolving line of credit bear interest at a rate per annum of, at the company's option, either the Base Rate, as defined in the credit agreement, plus an applicable margin of 2.00%, or the Eurodollar Rate, as defined in the credit agreement, plus an applicable margin of 3.00%. The B term loans bear interest at a rate per annum of, at the Company's option, either the Base Rate plus an applicable margin of 2.00% or 2.25% depending on the Company's consolidated secured net leverage ratio, or the Eurodollar Rate (which, in the case of such B term loans, is subject to a 1.00% floor) plus an applicable margin of 3.00% or 3.25% depending on the company's consolidated secured net leverage ratio. The company used approximately $1.68 billion of the proceeds of the new term loans drawn at closing to repay in full and terminate its existing secured credit facilities and to pay various fees and expenses associated with the transaction. The company may use the remaining proceeds of the new term loans and available capacity under the new revolving credit facility to finance permitted acquisitions, to finance capital expenditures, for working capital and for other general corporate purposes, subject to the terms of the credit agreement.

Alere Eyes Acquisitions

Alere Inc. (NYSE:ALR) mulls acquisitions. The Company announced that it may use the remaining proceeds of the new term loans and available capacity under the new revolving credit facility to finance permitted acquisitions, to finance capital expenditures, for working capital and for other general corporate purposes, subject to the terms of the credit agreement.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IM5:GR €48.16 EUR +0.043

IM5 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $146.37 USD -3.58
BioMerieux €96.11 EUR -0.16
Getinge AB kr201.30 SEK -3.00
MEDNAX Inc $74.81 USD -0.25
PerkinElmer Inc $52.24 USD -0.25
View Industry Companies
 

Industry Analysis

IM5

Industry Average

Valuation IM5 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book 3.1x
Price/Cash Flow 26.0x
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALERE INC, please visit www.alere.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.